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The counterfeiting C?lmedicinal products is a growing concern for patients, the pharmaceutical industry 
and national policy-makers worldwide. EU internal market rules for medicinal products for human 
use coupled by wide-ranging International cooperation, and proposed European legislative reforms 
are hoped to have a positive impact against the problem of counterfeit medicines - one of the greatest 
current threats to public health and safety. 
The WHO defines counterfeit medicines 
as "medicines that are deliberately and 
fraudulently mislabelled with respect to 
identity and/or source".l Since the first 
international initiative that addressed the 
problem of counterfeit medicines at the 
Conference of Experts on the Rational Use 
of Drugs in Nairobi in 1985, the worldwide 
import and export of counterfeit medicines 
has become a highly sophisticated criminal 
enterprise and a major public health 
concem The astronomical 118% increase 
in the number of medicinal products 
detained by customs authorities in 2008 
makes medicines the third largest specific 
product category in terms of quantities of 
intercepted counterfeit articles.2 This 
increase in customs discovery was largely 
due to the EU coordinated 'MEDI-FAKE' 
action which targeted customs control of 
counterfeit medicines over a two-month 
period in 2008 and led to the seizure of34 
million tablets, including antibiotics, 
antineoplastic, anti-malaria and lipid-
regulating medicines, as well as 
painkillers,and drug precursors. This by 
far (w~p,p,ded any previous results.3 
This growing global problem is being 
wnntp,rac.tp,o hy intp,mCltional p,nnP,flvol1l's 
of the WHO and the pharmaceutical 
industry, and through European legislative 
reforms. In 2006 the WHO launched the 
International Medical Products Anti-
Counterfeiting Taskforce (IMPACD which 
is a partnership comprising several 
stakeholders including international non-
govemmental organizations, regulatory 
authorities, enforcement agencies and 
phannaceutical manufacturers associations. 
FlUiherrnore, the European Directorate for 
the Quality of Medicines and Health care 
of The Council of Europe has set up a 
Committee ofExperts aimed at minimizing 
the public health risk posed by counterfeit 
medicinal products and related crimcs; 
whilst the US Food and Drug 
Administration (FDA) launched its 
Counterfeit Drug Task Force in July 2003 
to receive proposals from security experts, 
federal and State law enforcement officials, 
technology developers, manufacturers, 
wholesalers, retailers, consumer groups,. 
ami the general public, in onler to help 
deter counterfeit medicines. The European 
Medicines Agency (EMEA) also 
collaborates with member states in 
combating counterfeit medicinal products 
and has recently issued a warning about 
counterfeit medicines for the treatment of 
HINI influenza being sold over 
theintemet.4 
Directive 2001l83IEC on medicinal 
products for human use, as amended5 
includes provisions for manufacturing, 
importation, placing on the market, and 
wholesale distribution of medicinal 
products in the Community, as well as 
rules relating to active pharmaceutical 
ingredients used as starting materials. The 
Commission's proposal to amend this 
Directive6 aims to further optimise the 
functioning of the intemal market for 
medicinal products while ensuring a high 
level of protection of public health in the 
EU. 
The proposed amendments include: 
• Obligations for stakeholders, acting in 
the distribution chain and involved in 
the transactions but who do not actually 
handle the products; 
• A legal basis for the Commission to 
introduce obligatory safety-features (such 
as a serialisation number or a seal) on 
the packaging of prescription medicines; 
• Prohibition of manipulating (Le. removing 
and tampering with the packaging, or 
over-labelling) safety features on the 
packaging by intermediaries between 
the original manufacturer and the last 
stakeholder in the distribution chain 
(pharmacist/doctor/patient); 
• Obligatory audits of supplying wholesale 
distributors in order to ensure reliability 
of business partners; 
• Strengthened requirements for the 
importation of active pharmaceutical 
ingredients from third countries, if the 
regulatory framework in the respective 
third country does not ensure a sufficient 
level of protection of human health for 
products imported into the EU; 
• Audits of manufacturers of API; 
• Strengthened mandate for inspections 
including increased transparency of 
inspection results through publication 
in the EudraGMP database managed by 
theEMEA. 
The European Patients' Forum has 
published a Position Paper7 supporting the 
Commission's legislative proposal, 
focusing principally on patient-centred 
health care and patient involvement in 
counteracting the public health threat of 
counterfeit medicinal products. The 
European Federation of Pharmaceutical 
Industries and Associations (EFPIA) has 
however expressed concem that the patient 
safety would not be fully secured through 
the Commission's current proposals.8 
EFPIA has recommended a technological 
anti-counterfeiting strategy based on the 
integrity of the product packaging through 
the use of tamper-evident packaging or 
tampcr-rcsistnnt closures for all medicines, 
the use of overt, covert and forensic 
authentication features, and better product 
identification through one harmonized 
European coding of each individual pack. 
EFPIA has advocated the prohibition of 
repackaging in order to guarantee the 
integrity of the product throughout the 
entire supply chain. The latter proposal is 
highly controversial as it would severely 
lirrlltparailelirnportation.Parallel 
importation of a medicinal product is a 
lawful fOlm oftrllde within the Intemal 
Market based on article 28 of the EC Treaty 
and subject to the derogations provided 
by article 30 of the EC Treaty.9 
Tnrre:]<;ing proOllf't <;f.lfety is "Iso f.l kE'y 
priority in the US, with the focus being on 
the physical-chemical identifiers (PCIDs) 
in medicinal products. The FDA issued a 
Draft Guidance for Industry on Drug Anti-
counterfeitinglO in July 2009 on the use of 
inks, pigments, flavours, and other PCIDs 
by manufacturers to make medicinal 
product<; more difficult to duplicate by 
counterfeiters, and to make it easier to 
identifY the genuine version of the 
medicinal product. This is an important 
collaborative step between the FDA and 
drug manufacturers in making medicinal 
products more difficult to counterfeit. 
It is clear that the eradication of 
counterfeit medicines is a challenging 
undertaking which requires multi-
disciplinary collaboration between 
national govemments, the pharmaceutical 
industry amI intemational bodies; 
structured cooperation between regulatory 
autllorities and national law enforcement 
agencies sudr as the polil:e and l:Ustoms 
officials; as well as rigorous information 
campaigns directed at consumers. 
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